Increased prevalence of obstructive airways disease (OAD) in patients with ischemic heart disease (IHD) and hypertension (HT) Source: Eur Respir J 2007; 30: Suppl. 51, 122s Year: 2007
Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD Source: Eur Respir J 2008; 32: 962-969 Year: 2008
Cisplatin nephrotoxicity aggravated by cardiovascular disease and diabetes in lung cancer patients Source: Eur Respir J 2011; 37: 888-894 Year: 2011
The influence of diabetes type 2 (D2 ) on pulmonary hypertension (PH) in COPD patients Source: Eur Respir J 2005; 26: Suppl. 49, 60s Year: 2005
Pulmonary arterial hypertension (PAH) among end state renal disease (ESRD) patients under chronic hemodyalisis (HD) Source: Eur Respir J 2007; 30: Suppl. 51, 345s Year: 2007
Effect of roflumilast (ROF) on glucose levels in patients with COPD and diabetes mellitus type 2 (DM2) Source: Annual Congress 2010 - COPD: management Year: 2010
Initial experience of sildenafil in patients with congenital heart disease (CHD) associated pulmonary arterial hypertension (PAH) Source: Eur Respir J 2006; 28: Suppl. 50, 425s Year: 2006
Risk stratification of pulmonary arterial hypertension (PAH) associated with adult congenital heart disease (ACHD) Source: International Congress 2019 – Endpoints and risk assessment of pulmonary arterial hypertension Year: 2019
Systemic manifestations and comorbidities of COPD Source: Eur Respir J 2009; 33: 1165-1185 Year: 2009
Cardiovascular diseases (CVD), arterial hypertension (AH) and diabetes mellitus (DM) in a cohort of 609 COPD patients: Associations with the new GOLD classification 2011 Source: Annual Congress 2013 –Quality of life and respiratory symptoms in primary care COPD populations Year: 2013
COVID-19: Impact in adult patients with premorbid disease: Metabolic diseases (diabetes, obesity) Source: ERS Course 2021 - COVID-19: State of the art Year: 2021
Diabetes melittus (DM) risk for pulmonary tuberculosis (PTB) Source: Eur Respir J 2004; 24: Suppl. 48, 421s Year: 2004
Treatment of pulmonary hypertension (PH) and sickle cell disease (SCD) with sildenafil (SILD) therapy (walk-phasst): interim report Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009
Cystatin C as a marker of cardiovascular diseases in patients with obstructive sleep apnea (OSA) with concomitant diabetes mellitus type 2 (DM2) Source: Annual Congress 2013 –A metabolic medley: sleep disordered breathing Year: 2013
Frequency and pecularities of flow pulmonary tuberculosis (PT) in patients with different forms of diabetes mellitus (DM) in up-to-date conditions Source: Eur Respir J 2002; 20: Suppl. 38, 363s Year: 2002
Impact of borderline (BL) pulmonary hypertension (PH) in chronic lung diseases (CLD). Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020
Study of PFT‘s in patients with type 2 diabetes mellitus and diabetic neuropathy and microangiopathy Source: Annual Congress 2007 - Lung function and therapy in obstructive lung diseases Year: 2007
Presence of hypertension (HT), ischemic heart diseases (IHD) and a family history of hypertension are independently associated with reduced peak expiratory flow (PEF) values Source: Annual Congress 2012 - COPD beyond tobacco Year: 2012
Approach to the diagnostics of early carbon metabolism disorders and diabetes mellitus 2 type in COPD patients Source: Annual Congress 2013 –COPD diagnosis Year: 2013
Diabetes mellitus: a risk factor for idiopathic pulmonary fibrosis Source: Annual Congress 2007 - Clinical aspects of idiopathic pulmonary fibrosis Year: 2007